Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Mørk SK, Skadborg SK, Albieri B, Draghi A, Bol K, Kadivar M, Westergaard MCW, Stoltenborg Granhøj J, Borch A, Petersen NV, Thuesen N, Rasmussen IS, Andreasen LV, Dohn RB, Yde CW, Noergaard N, Lorentzen T, Soerensen AB, Kleine-Kohlbrecher D, Jespersen A, Christensen D, Kringelum J, Donia M, Hadrup SR, Marie Svane I. Mørk SK, et al. Among authors: yde cw. J Immunother Cancer. 2024 May 23;12(5):e008817. doi: 10.1136/jitc-2024-008817. J Immunother Cancer. 2024. PMID: 38782542 Free PMC article.
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH, Chamberlain CA, Borch TH, Nielsen M, Mørk SK, Kjeldsen JW, Lorentzen CL, Jørgensen LP, Riis LB, Yde CW, Met Ö, Donia M, Svane IM. Kverneland AH, et al. Among authors: yde cw. J Immunother Cancer. 2021 Oct;9(10):e003499. doi: 10.1136/jitc-2021-003499. J Immunother Cancer. 2021. PMID: 34607899 Free PMC article.
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Mørk SK, Kadivar M, Bol KF, Draghi A, Westergaard MCW, Skadborg SK, Overgaard N, Sørensen AB, Rasmussen IS, Andreasen LV, Yde CW, Trolle T, Garde C, Friis-Nielsen J, Nørgaard N, Christensen D, Kringelum JV, Donia M, Hadrup SR, Svane IM. Mørk SK, et al. Among authors: yde cw. Oncoimmunology. 2022 Jan 10;11(1):2023255. doi: 10.1080/2162402X.2021.2023255. eCollection 2022. Oncoimmunology. 2022. PMID: 35036074 Free PMC article.
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Nielsen M, et al. Among authors: yde cw. Cancer Immunol Res. 2022 Oct 4;10(10):1254-1262. doi: 10.1158/2326-6066.CIR-22-0326. Cancer Immunol Res. 2022. PMID: 35969233
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.
Borch A, Bjerregaard AM, Araujo Barbosa de Lima V, Østrup O, Yde CW, Eklund AC, Mau-Sørensen M, Barra C, Svane IM, Nielsen FC, Funt SA, Lassen U, Hadrup SR. Borch A, et al. Among authors: yde cw. Front Genet. 2023 Mar 23;14:1058605. doi: 10.3389/fgene.2023.1058605. eCollection 2023. Front Genet. 2023. PMID: 37035751 Free PMC article.
Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways.
Skadborg SK, Maarup S, Draghi A, Borch A, Hendriksen S, Mundt F, Pedersen V, Mann M, Christensen IJ, Skjøth-Ramussen J, Yde CW, Kristensen BW, Poulsen HS, Hasselbalch B, Svane IM, Lassen U, Hadrup SR. Skadborg SK, et al. Among authors: yde cw. Cancer Immunol Res. 2024 Sep 3;12(9):1202-1220. doi: 10.1158/2326-6066.CIR-23-0959. Cancer Immunol Res. 2024. PMID: 38885356 Free PMC article.
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Tuxen IV, Rohrberg KS, Oestrup O, Ahlborn LB, Schmidt AY, Spanggaard I, Hasselby JP, Santoni-Rugiu E, Yde CW, Mau-Sørensen M, Nielsen FC, Lassen U. Tuxen IV, et al. Among authors: yde cw. Clin Cancer Res. 2019 Feb 15;25(4):1239-1247. doi: 10.1158/1078-0432.CCR-18-1780. Epub 2018 Oct 1. Clin Cancer Res. 2019. PMID: 30274980 Clinical Trial.
55 results